<code id='45CD215577'></code><style id='45CD215577'></style>
    • <acronym id='45CD215577'></acronym>
      <center id='45CD215577'><center id='45CD215577'><tfoot id='45CD215577'></tfoot></center><abbr id='45CD215577'><dir id='45CD215577'><tfoot id='45CD215577'></tfoot><noframes id='45CD215577'>

    • <optgroup id='45CD215577'><strike id='45CD215577'><sup id='45CD215577'></sup></strike><code id='45CD215577'></code></optgroup>
        1. <b id='45CD215577'><label id='45CD215577'><select id='45CD215577'><dt id='45CD215577'><span id='45CD215577'></span></dt></select></label></b><u id='45CD215577'></u>
          <i id='45CD215577'><strike id='45CD215577'><tt id='45CD215577'><pre id='45CD215577'></pre></tt></strike></i>

          leisure time

          leisure time

          author:comprehensive    Page View:95
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more
          Death of patient in Alzheimer’s trial raises question of possible risks
          Death of patient in Alzheimer’s trial raises question of possible risks

          APSTockTheexperimentalAlzheimer’sdruglecanemab,hailedafteritslowedpatients’cognitivedeclineinaclinic

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Death of patient in Alzheimer’s trial raises question of possible risks

          APSTockTheexperimentalAlzheimer’sdruglecanemab,hailedafteritslowedpatients’cognitivedeclineinaclinic